公开(公告)号：EP2321690A2

公开(公告)日：2011-05-18

申请号：EP09752016.7

申请日：2009-07-31

申请人： Novartis AG

发明人： LINDACHER, Joseph, Michael ,  YE, Ming ,  PAYOR, Rick, Edward ,  SCHMID, Gregor, F.

IPC分类号： G02C7/04

摘要： A lens is provided that is capable of preventing or slowing the progression of myopia when worn by a person. The lens has a power profile that reduces on-axis and off-axis hyperopic defocus created by the optics of the eye by creating on-axis and off-axis myopic defocus. The on-axis and off-axis myopic defocus is created by providing light rays that pass through a central vision region of the optical portion and light rays that pass through a peripheral region of the optical portion an increase in positive (plus) power. The overall effect is to prevent or slow the progression of myopia without any perceptible degradation in the person's central vision.

公开(公告)号：EP2376976A1

公开(公告)日：2011-10-19

申请号：EP09795633.8

申请日：2009-12-16

申请人： Novartis AG ,  VISION CRC LIMITED

发明人： SCHMID, Gregor, F. ,  PAYOR, Rick, Edward ,  MARTINEZ, Aldo, Abraham

IPC分类号： G02C7/04

CPC分类号： G02C7/04 ,  G02C2202/08 ,  G02C2202/24

摘要： An ophthalmic lens series for reducing the progression of myopia through adequately correcting the peripheral retina, the series comprising more than one ophthalmic lens forming a series. Each ophthalmic lens of the series has a central power level common to the series. Each of the ophthalmic lenses of the series has one differential (peripheral minus central) power level selected from a variety of differential power levels. Providing a variety of differential power levels reduces the risk of over or under-correcting the peripheral retina of a particular eye.

公开(公告)号：EP2279445A1

公开(公告)日：2011-02-02

申请号：EP09733500.4

申请日：2009-04-20

申请人： Novartis AG ,  Brien Holden Vision Institute

发明人： MARTINEZ, Aldo, Abraham ,  HO, Arthur ,  SANKARIDURG, Padmaja, Rajagopal ,  LAZON, Percy, Fabian ,  HOLDEN, Brien, Anthony ,  PAYOR, Rick, Edward ,  SCHMID, Gregor, F.

IPC分类号： G02C7/02 ,  G02C7/04

CPC分类号： G02C7/06 ,  A61B3/0025 ,  G02C7/02 ,  G02C7/027 ,  G02C7/04 ,  G02C7/041 ,  G02C7/044 ,  G02C13/003 ,  G02C2202/08 ,  G02C2202/16 ,  G02C2202/24

摘要： Sets, kits or stocks of anti-myopia contact or spectacle lenses, along with methods for their use, that do not require a clinician to measure peripheral refractive error in the eyes of myopic patients. Extensive surveys have shown that lenses having peripheral powers or defocus set in accordance with central corrective power will cover almost all normal myopes not worse than -6 D central refractive error. In one example, a kit or set of lenses (50, FIG. 15) can have multiple parts or sub-sets (52, 54) each comprising a compartmented container (56a, 56b) with lenses (58a, 58b) arranged according to increments of central corrective power (59a, 59b). The lenses (58a) of the first part (52) have four steps (60a, 61a, 62a, 64a) of peripheral power or defocus to pro vide therapeutic effect and, while the lenses (58b) of the second part (54) also have four steps (60b, 61b, 62b, 64b), the level of therapeutic effect is higher. Other examples of sets, kits and stocks, as well as examples of lenses themselves, are disclosed together with methods of use.

摘要翻译： 抗近视接触镜或镜片的套件，套件或库存，以及使用方法，不需要临床医生测量近视患者眼睛的周边屈光不正。 广泛的调查显示，具有根据中心矫正力设置的外周功率或散焦的镜片将覆盖几乎所有正常的近距离不会比-6D中心屈光不正的差。 在一个示例中，套件或一组透镜（50，图15）可以具有多个部件或子组件（52,54），每个部件或子组件包括具有透镜（58a，58b）的分隔的容器（56a，56b），根据 中央矫正力的增量（59a，59b）。 第一部分（52）的透镜（58a）具有周边功率或散焦的四个台阶（60a，61a，62a，64a）以提供治疗效果，并且当第二部分（54）的透镜（58b）也具有 四个步骤（60b，61b，62b，64b），治疗效果水平较高。 集合，套件和股票的其他示例以及透镜本身的示例与所使用的方法一起公开。